EGFR, one of the ERBB family tyrosine kinases, is a widely useful therapeutic target in different types of cancer, and EGFR inhibitors have been approved by the United States Food and Drug Administration for the treatment of non-small cell lung cancer and pancreatic cancer [151]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.